Olmesartan Medoxomil is an angiotensin II receptor blocker (prodrug) indicated for hypertension. We supply it to US manufacturers of tablets and fixed-dose combinations.
Data from PubChem (CID 130881) and FDA’s substance registry
CAS number
144689-63-4
Molecular formula
C29H30N6O6
Molecular weight
558.6g/mol
FDA UNII
IUPAC name
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
InChIKey
UQGKUQLKSCSZGY-UHFFFAOYSA-N
- Appearance
- White to off-white powder.
- Solubility
- Practically insoluble in water and sparingly soluble in methanol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
A tetrazole sartan and an ester prodrug. Ask for nitrosamine and azido impurity data, and for the limit on olmesartan free acid, its main hydrolysis product.
On the US market
- Reference product
- BenicarNDA 021286
- Approved ANDAs
- 18 with a marketed product
- Approved forms and strengths
- Tablet 5 mg, 20 mg, 40 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com